Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Stryker Corp. (SYK)

NYSE:SYK

Stryker Corp. (SYK)

312.20
+6.56 (2.15%)
as of Jun 12, 2026, 8:00:00 pm Market Open.
258 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 12, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Stryker Corp. (SYK) faces challenges, including the recent cybersecurity incident affecting production and overall weakness in the health sector, but maintains a strong reputation as a leader in medical devices, particularly in orthopedics. Analysts highlight the attractiveness of the stock’s valuation, with expectations of significant earnings growth, forecasting $15 EPS by 2027 at a 20x PE ratio, driven by a 10% topline growth amidst an aging population. With a consistent market share gain from competitors like JNJ and ZBH, Stryker’s focus on robot-assisted surgeries in orthopedics is expected to double in growth over five years. Despite the current struggles in medtech, experts believe holding onto the stock could be beneficial in the long term, given its strong fundamentals and solid track record of acquisitions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
ZBH
TOP PICK

Stryker Corp.(SYK)

Aug 24, 2021
Has long held this. They produce medical devices for hips, knees and spines. The sector fell off during lockdowns due to no or few elective surgeries, however that is rebounding. Also, this is a demographic play as the population ages and needs such surgeries. Also, doctors stay loyal to a brand of medical devices. Trades at 25x earnings and has $3.7 billion in free cash. (Analysts’ price target is $288.43)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$271.21

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jul 22, 2021
(A Top Pick Jul 21/20, Up 37%) Great business. Demographic tailwind. User loyalty. Pandemic surgery slowdown created a backlog that's coming online now. Good free cashflow growth can be used to pay down debt and make acquisitions. Good upside for next several years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$256.87

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Jun 17, 2021
(A Top Pick Jun 26/20, Up 50%) Huge backlog of surgeries due to Covid. Really improves quality of life. Terrific brand loyalty. Good demographic play. More upside. Will keep raising dividend, buying back shares, making acquisitions.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$259.17

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Jun 07, 2021
With the opening of elective surgeries, it will start to pickup. The aging population will benefit them. They are head and shoulders above their peers.
Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$249.10

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

May 12, 2021
Rough time, as elective surgeries on hold during Covid. Good growth. Loyal users of products, good demographics. Acquisition of Wright Medical will work out well. Yield is 1.02%. (Analysts’ price target is $270.28)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$244.76

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
BUY

Stryker Corp.(SYK)

Apr 22, 2021

Not overly bullish on healthcare as a whole, as its growth may be less attractive. Likes medical devices, with a built-in backlog due to Covid. He owns SYK. There should be a significant pickup in procedures over the next 2 years. SYK has strong earnings growth, near a 1-year high. Also look at IHI, the medical devices ETF, packed with companies leading the healthcare sector.

Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$265.56

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Apr 06, 2021
They produce medical devices for hips, knees, hands and ankles. Elective surgeries are coming back after pandemic lockdowns. SYK's medical products reduce medical stays and drug use, which benefits American hospitals and patients. Again demographics are another tailwind. He expects good growth. SYK holds a lot of fresh cash to pay debt and the dividend. (Analysts’ price target is $251.00)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$248.48

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Mar 29, 2021
It has not done that well through the pandemic. Their appliances are used on an elective basis, so their installation got canceled by hospitals. Sales are expected to grow by 19% this year. (Analysts’ price target is $251.00)
Photo of Brett Girard, CPA, CA, CFABrett Girard, CPA, CA, CFA
Owned
Unlock Rating
$242.03

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Feb 11, 2021
(A Top Pick Jan 17/20, Up 16%) Medical devices and robotic-assisted surgery. Elective surgeries have resumed from last quarter.
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$243.70

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Feb 11, 2021
Great growth in robotics surgery. Uptick in elective surgery. Stands to benefit from pent-up demand as we return to normal. Likes it short- and medium-term. Yield is 1.03% (Analysts’ price target is $249.12)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$243.70

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Dec 24, 2020
(A Top Pick Dec 19/19, Up 15%) Medical healthcare. Great demographics, knee, hip, and spine replacements. Important to quality of life. Stock fell in March when elective surgeries were cancelled, but they're coming back. Would buy it here.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$237.06

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Oct 02, 2020
The gold standard in the industry. They have the best products, sales force and are quick to adapt. They are very innovative. As surgeries start to pick up, their products will see more demand. They are expected to earn $10/share. They are trading at a cheap multiple to normalized earnings. (Analysts’ price target is $214.35)
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$208.30

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Stryker Corp.(SYK)

Oct 01, 2020
(A Top Pick Jun 05/19, Up 13%) The downside of the pandemic is that elective surgeries were postponed. Knees, hips and other surgical procedures their products are used in were deferred. It is a backlog question. Demographically, more people will need their products.
Photo of Zachary Curry Zachary Curry
Owned
Unlock Rating
$206.51

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Stryker Corp.(SYK)

Sep 14, 2020
Medical devices. A lot of elective surgeries were put off but are now coming back. They acquired an ankle and wrist company. There is good international growth. There is a risk in the steep learning curve on these products. (Analysts’ price target is $213.91)
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$206.13

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
PARTIAL BUY

Stryker Corp.(SYK)

Aug 25, 2020

They're the leader in hips, knees and robotic surgeries. They were hit by COVID because elective surgeries stopped, but those have resumed now. Their revenue growth is 4-5 times higher than peers at 6-7% while peers like Johnson and Johnson were 1-2%. Dividends keep paying. Today is okay to enter this stock, though it's trading at 30x earnings. You can buy a half position now and see what happens.

Photo of David DriscollDavid Driscoll
Owned
Unlock Rating
$188.51

Stock price when the opinion was issued

$312.20

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical
Showing 61 to 75 of 170 entries
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica